MWN105 / Minwei Biotech - LARVOL DELTA

Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Shanghai Minwei Biotechnology Co., Ltd

New P1 trial • Diabetes • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Type 2 Diabetes Mellitus

Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity (clinicaltrials.gov) - P2 | N=120 | Completed | Sponsor: Shanghai Minwei Biotechnology Co., Ltd

New P2 trial • Genetic Disorders • Obesity

Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers (clinicaltrials.gov) - P1 | N=55 | Completed | Sponsor: Shanghai Minwei Biotechnology Co., Ltd

New P1 trial • Diabetes • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Type 2 Diabetes Mellitus

MWN105—A Next-Generation GLP-1/GIP/FGF21 Agonist for the Treatment of NASH (ADA 2025) - "The study assessed liver histology, metabolic biomarkers, body weight, and enzyme activity compared to tirzepatide. In the B6-Alms1-del NASH mouse model, MWN105 significantly reduced body weight, liver weight, and liver-to-body weight ratio. MWN105 demonstrates potent metabolic and antifibrotic effects, addressing key NASH pathologies. MWN105 has a potential best-in-class therapeutic profile for NASH. MWN105 has obtained IND clearance in both the U.S. and China and Further Phase I clinical study is on-going."

Late-breaking abstract • Diabetes • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • FGF21